Schering-Plough Corporation: Q1 2005 Financial Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2005, for Schering-Plough Corporation. The company operates in three segments: Prescription Pharmaceuticals, Consumer Health Care, and Animal Health. The reporting period reflects a strategic turnaround phase, characterized by significant sales growth driven by new product launches and a joint venture with Merck, offset by ongoing regulatory challenges and cash flow pressures.
Key Financial Metrics
| Metric | Q1 2005 | Q1 2004 | Change |
|---|---|---|---|
| Net Sales | $2,369 million | $1,963 million | +21% |
| Net Income | $127 million | $(73) million | Turnaround to Profit |
| Net Income Available to Common Shareholders | $105 million | $(73) million | N/A |
| Diluted EPS | $0.07 | $(0.05) | N/A |
| Operating Cash Flow | $200 million | $229 million | -13% |
| Cash and Equivalents (End of Period) | $3,912 million | $3,932 million | Flat |
| Short-Term Borrowings | $398 million | $1,569 million | Significant Reduction |
| Long-Term Debt | $2,392 million | $2,392 million | No Change |
Margins: Cost of sales was 37.5% of net sales (down from 37.7%). Selling, general, and administrative (SG&A) expenses were 45.6% of net sales (down from 46.6%). Research and development (R&D) was 16.2% of net sales (down from 19.0%).
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 21% year-over-year, driven by a 25% increase in Prescription Pharmaceuticals sales. Key drivers included the launch of AVELOX and CIPRO (licensed from Bayer), growth in REMICADE (+33%), NASONEX (+30%), and TEMODAR (+52%).
- Equity Income Surge: Equity income from the cholesterol joint venture with Merck jumped from $78 million to $220 million. This was due to higher sales of ZETIA and VYTORIN, a favorable profit-sharing structure for the first $300 million of ZETIA sales, and a $14 million milestone recognition for European approvals.
- Special Charges: Special charges decreased significantly from $70 million in Q1 2004 to $27 million in Q1 2005. The 2005 charges primarily related to employee termination costs at a manufacturing facility, whereas 2004 included significant asset impairment charges.
- Debt Reduction: The company reduced short-term borrowings by approximately $1.17 billion during the quarter, primarily through the repayment of commercial paper.
Outlook, Risks, and Management Commentary
Management Commentary: Management notes that while Q1 2005 results improved, they may not be indicative of future periods due to favorable timing factors (e.g., joint venture profit sharing, milestones). The company is repatriating foreign earnings under the American Jobs Creation Act of 2004 to fund U.S. cash needs, as U.S. operations continue to generate negative cash flow.
Risks and Contingencies:
- Regulatory Consent Decree: The company is subject to an FDA consent decree regarding manufacturing practices. Failure to meet revalidation deadlines by late 2005 could result in significant fines (up to $50 million annually) or production halts.
- Legal Investigations: Ongoing investigations by the U.S. Attorney's Office in Massachusetts regarding sales and marketing practices pose significant financial risk. A liability of $250 million is recorded, but the final settlement could be materially higher.
- Patent Expirations and Competition: The company faces intense competition and generic entry for key products like REBETOL and CLARITIN. The loss of exclusivity for major franchises has historically strained cash flow.
- Liquidity: Management anticipates that worldwide dividends and capital expenditures will exceed operating cash flow in 2005. The company relies on repatriated funds and a $1.5 billion revolving credit facility to maintain liquidity.
Investor Verification Checklist
- Joint Venture Dependency: Verify the sustainability of the cholesterol joint venture income, noting that a significant portion of Q1 profits was driven by a specific profit-sharing tier and a one-time milestone.
- Regulatory Compliance Status: Monitor progress on the FDA consent decree revalidation deadlines (September and December 2005) to assess the risk of potential fines or production stoppages.
- Legal Exposure: Review updates on the Massachusetts investigation to determine if the $250 million accrual remains sufficient or if additional reserves are needed.
- Cash Flow Sustainability: Assess the timeline for repatriating foreign earnings and the company's ability to fund U.S. operations without further dilution or debt increases.
- Product Pipeline: Evaluate the commercial performance of new launches (AVELOX, CIPRO, TEMODAR) to determine if they can offset declines in legacy products like REBETOL and CLARITIN.